- Cellect Biotechnology Ltd. - American Depositary Shares APOP fell 29.5 percent to $4.31. Cellect Biotechnology shares surged Thursday after the company disclosed that it has received a notice of allowance from the US Patent Office protecting its technology in multiple key indications.
- Uranium Resources, Inc. URRE shares dropped 25.2 percent to $2.35 after the company reported the pricing of $9.7 million public offering.
- Skyline Medical Inc SKLN shares declined 19.5 percent to $2.27. Skyline Medical priced its stock and warrant offering for gross proceeds of $3.9 million.
- Marinus Pharmaceuticals Inc MRNS shares fell 15.9 percent to $1.18. Marinus Pharmaceuticals shares have declined 75.99 percent over the past 52 weeks, while the S&P 500 index has climbed 20.11 percent in the same period.
- Inventure Foods Inc SNAK declined 12.2 percent to $6.39. DA Davidson downgraded Inventure Foods from Buy to Neutral and lowered the price target from $10.00 to $8.00.
- Ryerson Holding Corp RYI dropped 9.2 percent to $12.30. Ryerson projects Q4 loss of $14 million to $11 million including LIFO expense.
- GameStop Corp. GME dropped 8.3 percent to $22.66. GameStop slashed its comparable sales guidance for the fourth quarter and full year after it reported “disappointing” holiday sales on industry weakness, pricing pressure and lower store traffic.
- Biocept Inc BIOC shares fell 6.6 percent to $1.99. Biocept shares have dropped 55.35 percent over the past 52 weeks, while the S&P 500 index has climbed 20.11 percent in the same period.
- Infosys Ltd ADR INFY shares declined 5.4 percent to $14.43. Infosys posted Q3 earnings of $0.24 per share on revenue of $2.55 billion.
- MYOS RENS Technology Inc MYOS shares fell 4 percent to $3.60 after dropping 45.01 percent on Thursday.
- Actuant Corporation ATU dropped 3 percent to $26.05. RBC Capital downgraded Actuant from Outperform to Sector Perform.
- Alamos Gold Inc (US) AGI slipped around 3 percent to $8.15. Credit Suisse downgraded Alamos Gold from Outperform to Neutral.
Market News and Data brought to you by Benzinga APIs
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in